Australia’s viral vector manufacturing capability is set to support the development of a novel gene therapy and light-based treatment approach for obstructive sleep apnoea under a new collaboration involving the Viral Vector Manufacturing Facility, Optosleep and UNSW Sydney.
VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea
August 13, 2026 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
Australia cannot afford complacency on life sciences, AusBiotech warns at 40
October 8, 2026 - - Latest News -
Life sciences sector warns that tax overhaul could push clinical trials offshore
October 8, 2026 - - Latest News -
Moderna and CSIRO launch five year biosecurity collaboration focused on Hendra vaccine
October 8, 2026 - - Latest News
